# 4D Molecular Therapeutics, Inc. (FDMT) MD&A by fiscal year

Verbatim Item 7 Management's Discussion and Analysis sections from 4D Molecular Therapeutics, Inc.'s 10-K filings, one page per fiscal year. Extracted from SEC filings with the same bounded parser for every year. Filer text, not grepcent analysis or investment advice.

- [FY 2025 MD&A](/company/FDMT/mda/fy2025/): filed 2026-03-18; accession 0001193125-26-114075 (https://www.sec.gov/Archives/edgar/data/1650648/000119312526114075/fdmt-20251231.htm); latest 10-K
- [FY 2024 MD&A](/company/FDMT/mda/fy2024/): filed 2025-02-28; accession 0000950170-25-030056 (https://www.sec.gov/Archives/edgar/data/1650648/000095017025030056/fdmt-20241231.htm)
- [FY 2023 MD&A](/company/FDMT/mda/fy2023/): filed 2024-02-29; accession 0000950170-24-023183 (https://www.sec.gov/Archives/edgar/data/1650648/000095017024023183/fdmt-20231231.htm)
- [FY 2022 MD&A](/company/FDMT/mda/fy2022/): filed 2023-03-15; accession 0000950170-23-008142 (https://www.sec.gov/Archives/edgar/data/1650648/000095017023008142/fdmt-20221231.htm)
- [FY 2021 MD&A](/company/FDMT/mda/fy2021/): filed 2022-03-28; accession 0000950170-22-004794 (https://www.sec.gov/Archives/edgar/data/1650648/000095017022004794/fdmt-20211231.htm)

Back to /company/FDMT/